share_log

Jefferies Downgrades Avalo Therapeutics to Underperform, Announces $3 Price Target

Benzinga Real-time News ·  Feb 8, 2023 08:18

Jefferies analyst Chris Howerton downgrades Avalo Therapeutics (NASDAQ:AVTX) from Hold to Underperform and announces $3 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment